2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 377

Pain and Quality of Life Profiles in Colombian Patients with Rheumatoid Arthritis: A Mixed Cluster Analysis
Abstract Number: 1983

Pain and Sensitization in Women with Aromatase Inhibitor-Associated Arthralgias
Abstract Number: 379

Pain Catastrophizing Decreases in RA Patients Starting, Adding or Switching a DMARD
Abstract Number: 3048

Pain Severity As a Mediator of the Effect of Depressive Symptoms on Physical Performance in Knee Osteoarthritis
Abstract Number: 1525

Pain, Physical Function, and Worry (But Not Depression and Poor Sleep) Lead to Greater Fatigue in RA
Abstract Number: 3173

Pan-PPAR Agonist IVA337 Is Effective in the Prevention of Experimental Lung Fibrosis and Related Pulmonary Hypertension
Abstract Number: 685

Paradoxical Psoriasis Secondary to Anti-Tnfa Agents in Patients with Ankylosing Spondylitis: A Nationwide Population-Based Cohort Study
Abstract Number: 1915

Partial Elimination of Intestinal Microbiota Dampens T Helper 17 Cell Differentiation and Established Collagen-Induced Arthritis in Mice
Abstract Number: 3111

Pathogenic T Cell Responses in Systemic Sclerosis Is Shaped By Novel Cytokine Axis in the Microenvironment: A Multidimensional, High Throughput Analysis
Abstract Number: 2254

Patient Adherence with Biologic Therapy in Rheumatoid Arthritis: A Real-World Review of Compliance
Abstract Number: 740

Patient Adherence with Mycophenolate Mofetil Therapy in a Systemic Lupus Erythematosus Cohort: A Multi-Factorial Assessment
Abstract Number: 2394

Patient and Parent Global Assessments of Disease Impact in Pediatric Localized Scleroderma: Correlates of Patient Reported Health-Related Quality of Life and Parent Reported Family Impact Domains
Abstract Number: 1428

Patient Attitudes Towards Being Prescribed Biosimilars in Inflammatory Autoimmune Diseases in Germany
Abstract Number: 2023

Patient Barriers to Osteoporosis Screening in a Medical Clinic: Why Underserved Patients Who Follow Recommendations for Colonoscopy and Mammography Fail to Get Their DXA Scans
Abstract Number: 2493

Patient Characteristics and Medication Utilization Patterns of Infliximab-Treated Rheumatoid Arthritis Patients Subsequently Transitioned to Intravenous Golimumab

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].